JQ-1

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

BET inhibitor

Related drugs:

‹

›

MAF overexpression	Multiple Myeloma	MAF overexpression	Multiple Myeloma	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3
EPCAM expression	Triple Negative Breast Cancer	EPCAM expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
SOX9 expression	Triple Negative Breast Cancer	SOX9 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
GJA1 expression	Triple Negative Breast Cancer	GJA1 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
CD24 expression	Triple Negative Breast Cancer	CD24 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
BRD4 overexpression	Retinoblastoma	BRD4 overexpression	Retinoblastoma	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	JQ-1 + panobinostat Sensitive: D – Preclinical JQ-1 + panobinostat Sensitive : D	JQ-1 + panobinostat Sensitive: D – Preclinical JQ-1 + panobinostat Sensitive : D
MLL rearrangement	Leukemia	MLL rearrangement	Leukemia	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
P2RY8-CRLF2 fusion	B Acute Lymphoblastic Leukemia	P2RY8-CRLF2 fusion	B Acute Lymphoblastic Leukemia	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
MYC expression	Multiple Myeloma	MYC expression	Multiple Myeloma	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D
KRAS Q61K	Non Small Cell Lung Cancer	KRAS Q61K	Non Small Cell Lung Cancer	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
KRAS G12S	Non Small Cell Lung Cancer	KRAS G12S	Non Small Cell Lung Cancer	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
MYCL overexpression	Multiple Myeloma	MYCL overexpression	Multiple Myeloma	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
FLT3 D835V	Acute Myelogenous Leukemia	FLT3 D835V	Acute Myelogenous Leukemia	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
FLT3 F691L	Acute Myelogenous Leukemia	FLT3 F691L	Acute Myelogenous Leukemia	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
PRC2 mutation	T Acute Lymphoblastic Leukemia	PRC2 mutation	T Acute Lymphoblastic Leukemia	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
FBXW7 underexpression	Breast Cancer	FBXW7 underexpression	Breast Cancer	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D
FBXW7 underexpression	Breast Cancer	FBXW7 underexpression	Breast Cancer	JQ-1 + S63845 Sensitive: D – Preclinical JQ-1 + S63845 Sensitive : D	JQ-1 + S63845 Sensitive: D – Preclinical JQ-1 + S63845 Sensitive : D
CDKN2A deletion	Pancreatic Ductal Adenocarcinoma	CDKN2A deletion	Pancreatic Ductal Adenocarcinoma	palbociclib + JQ-1 Sensitive: D – Preclinical palbociclib + JQ-1 Sensitive : D	palbociclib + JQ-1 Sensitive: D – Preclinical palbociclib + JQ-1 Sensitive : D
FAT1 mutation	Squamous Cell Carcinoma of Head and Neck	FAT1 mutation	Squamous Cell Carcinoma of Head and Neck	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
BRD4 overexpression	Endometrial Cancer	BRD4 overexpression	Endometrial Cancer	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D

JQ-1

Associations
(27)

Associations
(27)

JQ-1

Associations(27)

Associations(27)

Associations
(27)

Associations
(27)